Folic Acid Potentiates the Effect of Memantine on Spatial Learning and Neuronal Protection in an Alzheimer's Disease Transgenic Model

Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Journal of Alzheimer's disease: JAD (Impact Factor: 4.15). 02/2010; 20(2):607-15. DOI: 10.3233/JAD-2010-1396
Source: PubMed


Folic acid deficiency and hyperhomocysteinemia potentiate amyloid-beta (Abeta) neuron toxicity. Memantine, an NMDA antagonist used in moderate to severe AD, is considered to be neuroprotective. We propose that folic acid might have a synergistic effect for memantine in protecting neurons from Abeta accumulation. We treated 8-month-old Tg2576 transgenic mice with memantine (30 mg/kg/day) with or without folic acid (8 mg/kg/day) for 4 months. Escape latencies in the Morris water maze were significantly shorter in the folic acid-memantine treatment group Tg(+)_M+F compared to both the non-treatment transgenic controls Tg(+) and the memantine-treatment group Tg(+)_M (both p < 0.05). Analysis of Abeta40 and Abeta42 showed lower brain loads in both treatment groups but this did not reach statistical significance. Histopathology analysis showed that Tg(+)_M+F had lower ratios of neuronal damage than Tg(+) (p < 0.001) and Tg(+)_M (p< 0.005). DNA analysis revealed that in the Tg(+)M_+F group, transcription was upregulated in 72 brain genes involved in neurogenesis, neural differentiation, memory, and neurotransmission compared to the Tg(+)_M group. In conclusion, we found that folic acid may potentiate the effect of memantine on spatial learning and neuronal protection. The benefit of combination therapy may be through co-action on the methylation-controlled Abeta production, and modification of brain gene expression.

Download full-text


Available from: Jyh-Feng Lu
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: More than a decade after the first approval of the use of acetylcholine esterase inhibitor on patients with Alzheimer's disease, we still not have a single treatment or combination therapy that can effectively stop or reverse the relentless progression of such neurodegenerative disease. Recently therapeutics targeting amyloid hypothesis have undergone scrutiny by many clinical trials. These include gamma secretase inhibitor for reducing beta amyloid formation, agents for preventing aggregation of amyloid oligomers, and immunotherapy for enhancing clearance of amyloid and plaque. Therapies targeting hyperphosphorylated tau is another promising mechanism to be tackled with. Other agents enforcing mitochondria functions, enhancing serotonin receptors, modulating advanced glycation end products, and neurotrophic factors, as well as other therapies are also emerging. We review current treatments and therapeutic strategies already undergone different stage of clinical trails in this report. We propose that therapeutics of various combination composed of symptomatic treatments and disease modifying therapies will become standard regimens of AD treatment with much better efficacy than current approaches.
    Full-text · Article · Dec 2010 · Acta neurologica Taiwanica
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the term 'epigenetics' was coined nearly seventy years ago, its critical function in memory processing by the adult CNS has only recently been appreciated. The hypothesis that epigenetic mechanisms regulate memory and behavior was motivated by the need for stable molecular processes that evade turnover of the neuronal proteome. In this article, we discuss evidence that supports a role for neural epigenetic modifications in the formation, consolidation and storage of memory. In addition, we will review the evidence that epigenetic mechanisms regulate synaptic plasticity, a cellular correlate of memory. We will also examine how the concerted action of multiple epigenetic mechanisms with varying spatiotemporal profiles influence selective gene expression in response to behavioral experience. Finally, we will suggest key areas for future research that will help elucidate the complex, vital and still mysterious, role of epigenetic mechanisms in neural function and behavior.
    Full-text · Article · Apr 2011 · Epigenomics
  • [Show abstract] [Hide abstract]
    ABSTRACT: We review studies testing performance on tasks putatively tapping spatial memory in the Tg2576 mouse model of Alzheimer's disease (AD). This model exhibits age-dependent elevation of amyloid-β in the hippocampal formation and elsewhere in the brain. From 49 articles in all, we reviewed Tg2576 performance on five spatial memory tasks: the reference memory version of the Morris water maze, continuous Y-maze alternation, discrete forced-choice T-maze alternation, the radial arm water maze, and the circular platform maze (Barnes maze). Proportionally, the likelihood of detecting significant impairment in Tg2576 mice (relative to age-matched controls) was found to be: highest with the use of T-maze alternation and the radial arm water maze; intermediate when using the Morris water maze and continuous Y-maze alternation; and lowest when using the circular platform maze. These results are indicative rather than conclusive, but have implications for testing cognitive function in Tg2576 mice and, potentially, other AD rodent models. The apparent sensitivity of the T-maze alternation task and reduced sensitivity of the Morris water maze task (reference memory version) are discussed. We also consider limitations and potential improvements in assessing cognitive impairment in dementia models.
    No preview · Article · May 2011 · Journal of Alzheimer's disease: JAD
Show more